Related Experiment Video
Updated: Jul 7, 2026

Reverse Yeast Two-hybrid System to Identify Mammalian Nuclear Receptor Residues that Interact with Ligands and/or Antagonists
Published on: November 15, 2013
Nuclear receptor CAR requires early growth response 1 to activate the human cytochrome P450 2B6 gene
Kaoru Inoue1, Masahiko Negishi
1Pharmacogenetics Section, Laboratory of Reproductive and Developmental Toxicology, NIEHS, National Institutes of Health, Research Triangle Park, North Carolina 27709, USA.
Abstract:
The nuclear receptor CAR (constitutive active/androstane receptor) is a drug-sensing transcription factor, regulating the hepatic genes that encode various drug-metabolizing enzymes. We have now characterized the novel regulatory mechanism by which the signal molecule EGR1 (early growth response 1) determines CAR-mediated activation of the human CYP2B6 (cytochrome P450 2B6) gene. The CYP2B6 enzyme metabolizes commonly used therapeutics and also activates pro-drugs. The CAR directly binds to the distal enhancer element of the CYP2B6 promoter, which is essential in converging to its drug-sensing function onto promoter activity. However, this binding alone is not sufficient to activate the CYP2B6 promoter; the promoter requires EGR1 to enable CAR to activate the CYP2B6 promoter. Upon stimulation by protein kinase C, EGR1 directly binds to the proximal promoter and coordinates the nearby HNF4alpha (hepatocyte-enriched nuclear factor 4alpha) with CAR at the distal enhancer element to activate the promoter. Thus, synergy of drug activation and the stimulation of cellular signal are necessary for CAR to activate the CYP2B6 gene.
Insights
The constitutive active/androstane receptor (CAR) requires early growth response 1 (EGR1) to activate the CYP2B6 gene, which metabolizes drugs. EGR1 links cellular signals with CAR
Area of Science:
- Pharmacology
- Molecular Biology
- Genetics
Background:
- The constitutive active/androstane receptor (CAR) is a key drug-sensing transcription factor regulating hepatic drug-metabolizing enzymes.
- The human CYP2B6 gene encodes a crucial enzyme involved in metabolizing common therapeutics and activating prodrugs.
- Understanding CAR's regulatory mechanisms is vital for drug metabolism and efficacy.
Purpose of the Study:
- To elucidate the novel regulatory mechanism of CAR-mediated activation of the human CYP2B6 gene.
- To investigate the role of the signal molecule early growth response 1 (EGR1) in CYP2B6 gene activation.
- To determine the synergistic requirements for CAR to activate CYP2B6 gene expression.
Main Methods:
- Characterization of gene regulation using molecular biology techniques.
- Analysis of transcription factor binding to promoter and enhancer elements.
- Investigating protein-protein interactions and signaling pathways.
Main Results:
- CAR directly binds to the distal enhancer of the CYP2B6 promoter, but this binding alone is insufficient for activation.
- Early growth response 1 (EGR1) is essential for CAR to activate the CYP2B6 promoter.
- EGR1, upon protein kinase C stimulation, binds the proximal promoter and coordinates with HNF4alpha and CAR at the distal enhancer.
Conclusions:
- CAR-mediated activation of the human CYP2B6 gene requires a synergistic interplay between drug sensing and cellular signaling pathways.
- EGR1 acts as a critical mediator, linking cellular signals to CAR's function at the CYP2B6 promoter.
- Both CAR and EGR1, along with HNF4alpha, are necessary for robust CYP2B6 gene activation.
Related Concept Videos
Transducer Mechanism: Nuclear Receptors
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
Regulation of Nuclear Protein Sorting
Signal Transduction: Overview
Typically, signal transduction involves three...
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
Cell Specific Gene Expression
Intracellular Hormone Receptors
